Screening HLA to Prevent Severe Drug Reactions-A Devil's Advocate Perspective.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Attribution of causality in Stevens-Johnson syndrome/toxic epidermal necrolysis.The ocular surface · 2025
   Review
2. Assessment of Need for Improved Identification of a Culprit Drug in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.JAMA dermatology · 2023
   Article

Corrections and comments

• Commented on by
  Implementation of Genetic Screening to Prevent Severe Cutaneous Adverse Drug Reactions Is Crucial-Rebuttal From the Devil's Antagonist-Reply.2020
• Commented on by
  Implementation of Genetic Screening to Prevent Severe Cutaneous Adverse Drug Reactions Is Crucial-Rebuttal From the Devil's Antagonist.2020
• Comment on
  Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.2019

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as